Executive Director, Investor Relations and Corporate Communications

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.

Position Overview 

The Executive Director, Investor Relations will serve as the primary point of contact for the investment community and play a critical role in shaping Immunome’s external communications strategy. Reporting to the Chief Financial Officer, this leader will be responsible for articulating the company’s strategy, progress, and value proposition to investors, analysts, and other key financial stakeholders. The role requires deep understanding of the biotechnology sector and the ability to translate complex scientific and clinical information into clear, compelling narratives that enhance Immunome’s visibility and credibility in the capital markets. 

Responsibilities 

Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).